Comparative Pharmacology
Head-to-head clinical analysis: AVALIDE versus HYDROPRES 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVALIDE versus HYDROPRES 25.
AVALIDE vs HYDROPRES 25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avalide is a combination of an angiotensin II receptor blocker (irbesartan) and a thiazide diuretic (hydrochlorothiazide). Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine uptake, leading to decreased sympathetic outflow.
AVALIDE (irbesartan/hydrochlorothiazide) is available as tablets containing 150/12.5 mg, 300/12.5 mg, or 300/25 mg. The typical starting dose is 150/12.5 mg once daily, titrated to 300/12.5 mg once daily as needed. Maximum dose is 300/25 mg once daily.
1 tablet orally once daily, each tablet contains hydrochlorothiazide 25 mg and reserpine 0.125 mg. Dosage may be increased to 2 tablets daily if needed.
None Documented
None Documented
Irbesartan: 11-15 h (terminal), HCTZ: 6-15 h (terminal). Clinical context: Steady state reached in 3-5 days; allows once-daily dosing.
Hydrochlorothiazide: 6-15 hr; reserpine: 50-100 hr (terminal, with prolonged adrenergic depletion lasting days)
Renal: HCTZ ~70% unchanged; Irbesartan ~20% unchanged, remainder as metabolites via biliary (60%) and renal (20%). Combined: Renal ~50%, biliary/fecal ~50%.
Renal: hydrochlorothiazide 70% unchanged, reserpine ~30% unchanged; fecal: reserpine ~60% metabolites
Category C
Category C
ARB and Thiazide Diuretic Combination
Thiazide Diuretic Combination